Literature DB >> 34260028

MicroRNAs Regulating Autophagy in Neurodegeneration.

Qingxuan Lai1, Nikolai Kovzel1, Ruslan Konovalov1, Ilya A Vinnikov2.   

Abstract

Social and economic impacts of neurodegenerative diseases (NDs) become more prominent in our constantly aging population. Currently, due to the lack of knowledge about the aetiology of most NDs, only symptomatic treatment is available for patients. Hence, researchers and clinicians are in need of solid studies on pathological mechanisms of NDs. Autophagy promotes degradation of pathogenic proteins in NDs, while microRNAs post-transcriptionally regulate multiple signalling networks including autophagy. This chapter will critically discuss current research advancements in the area of microRNAs regulating autophagy in NDs. Moreover, we will introduce basic strategies and techniques used in microRNA research. Delineation of the mechanisms contributing to NDs will result in development of better approaches for their early diagnosis and effective treatment.
© 2021. Science Press.

Entities:  

Year:  2021        PMID: 34260028     DOI: 10.1007/978-981-16-2830-6_11

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  386 in total

1.  A uniform system for microRNA annotation.

Authors:  Victor Ambros; Bonnie Bartel; David P Bartel; Christopher B Burge; James C Carrington; Xuemei Chen; Gideon Dreyfuss; Sean R Eddy; Sam Griffiths-Jones; Mhairi Marshall; Marjori Matzke; Gary Ruvkun; Thomas Tuschl
Journal:  RNA       Date:  2003-03       Impact factor: 4.942

2.  Tolerance for mutations and chemical modifications in a siRNA.

Authors:  Mohammed Amarzguioui; Torgeir Holen; Eshrat Babaie; Hans Prydz
Journal:  Nucleic Acids Res       Date:  2003-01-15       Impact factor: 16.971

3.  CleaveLand: a pipeline for using degradome data to find cleaved small RNA targets.

Authors:  Charles Addo-Quaye; Webb Miller; Michael J Axtell
Journal:  Bioinformatics       Date:  2008-11-18       Impact factor: 6.937

4.  Comparative analysis of the efficiency and specificity of myeloid-Cre deleting strains using ROSA-EYFP reporter mice.

Authors:  Clare L Abram; Gray L Roberge; Yongmei Hu; Clifford A Lowell
Journal:  J Immunol Methods       Date:  2014-05-22       Impact factor: 2.303

5.  PARK2 patient neuroprogenitors show increased mitochondrial sensitivity to copper.

Authors:  Asad A Aboud; Andrew M Tidball; Kevin K Kumar; M Diana Neely; Bingying Han; Kevin C Ess; Charles C Hong; Keith M Erikson; Peter Hedera; Aaron B Bowman
Journal:  Neurobiol Dis       Date:  2014-10-12       Impact factor: 5.996

6.  Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis.

Authors:  David Adams; Alejandra Gonzalez-Duarte; William D O'Riordan; Chih-Chao Yang; Mitsuharu Ueda; Arnt V Kristen; Ivailo Tournev; Hartmut H Schmidt; Teresa Coelho; John L Berk; Kon-Ping Lin; Giuseppe Vita; Shahram Attarian; Violaine Planté-Bordeneuve; Michelle M Mezei; Josep M Campistol; Juan Buades; Thomas H Brannagan; Byoung J Kim; Jeeyoung Oh; Yesim Parman; Yoshiki Sekijima; Philip N Hawkins; Scott D Solomon; Michael Polydefkis; Peter J Dyck; Pritesh J Gandhi; Sunita Goyal; Jihong Chen; Andrew L Strahs; Saraswathy V Nochur; Marianne T Sweetser; Pushkal P Garg; Akshay K Vaishnaw; Jared A Gollob; Ole B Suhr
Journal:  N Engl J Med       Date:  2018-07-05       Impact factor: 91.245

7.  Chaperone-mediated autophagy markers in Parkinson disease brains.

Authors:  Lydia Alvarez-Erviti; Maria C Rodriguez-Oroz; J Mark Cooper; Cristina Caballero; Isidro Ferrer; Jose A Obeso; Anthony H V Schapira
Journal:  Arch Neurol       Date:  2010-08-09

8.  Influence of microRNA deregulation on chaperone-mediated autophagy and α-synuclein pathology in Parkinson's disease.

Authors:  L Alvarez-Erviti; Y Seow; A H V Schapira; M C Rodriguez-Oroz; J A Obeso; J M Cooper
Journal:  Cell Death Dis       Date:  2013-03-14       Impact factor: 8.469

9.  Control of small inhibitory RNA levels and RNA interference by doxycycline induced activation of a minimal RNA polymerase III promoter.

Authors:  Lahouari Amar; Mathieu Desclaux; Nicole Faucon-Biguet; Jacques Mallet; Roland Vogel
Journal:  Nucleic Acids Res       Date:  2006-03-06       Impact factor: 16.971

10.  Trial design and rationale for APOLLO, a Phase 3, placebo-controlled study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy.

Authors:  David Adams; Ole B Suhr; Peter J Dyck; William J Litchy; Raina G Leahy; Jihong Chen; Jared Gollob; Teresa Coelho
Journal:  BMC Neurol       Date:  2017-09-11       Impact factor: 2.474

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.